Mutant-Specific Antibody
Mutation-specific antibodies are designed to recognize and bind to specific mutated forms of proteins. These mutations often occur in cancer cells, making mutation-specific antibodies valuable tools in both research and clinical settings. OriGene has created many mutant-specific antibodies highly specific to the targeted protein.
Gene | Mutation | Description | SKU |
---|---|---|---|
BRAF | V600E | Anti-BRAF(V600E) Rabbit Monoclonal Antibody | |
KRAS | G12D | Anti-KRAS(G12D) Rabbit Monoclonal Antibody | |
IDH1 | R132H | Anti-IDH1(R132H) Rat Monoclonal Antibody |
Identification of Mutant Antibody with CytoSections™
What are CytoSections?
OriGene has developed a tool for antibody validation called CytoSections. CytoSections are FFPE sections of transiently transfected cDNA specific gene targets overexpressed in mammalian cells. They are a cost-effective, easily renewable, and unlimited source of controls for validating mutant-specific antibodies. Below, we describe how OriGene used CytoSections to validate an antibody specific to the key IDH1(R132H) mutation for use in IHC assays.
CytoSections either over-expressing IDH1 or mutant IDH1( R132H) and untransfected CytoSections were used to screen two different mutant-specific antibodies against IDH1(R132H). The results are shown below
Use of the DDK antibody (
), resulted in positive (brown) staining, in WT (IDH1) and mutant (IDH1(R132H) CytoSections (1A and 1B) respectively). This demonstrates that the CytoSections are expressing either the DDK-tagged IDH1 WT construct, or the mutant construct, as expected. There is no positive staining in the untransfected negative control (1C). WT IDH1 antibody ( ) detected both WT (2A) and mutant IDH1(R132H) (2B) while the untransfected control (2C) is negative.
Development and Specificity
It is difficult to develop mutant-specific antibodies. The key factors to keep in mind are:
Targeted Mutations: Mutation-specific antibodies are engineered to target proteins that have undergone specific point mutations, insertions, deletions, or other alterations. These mutations can alter the protein's structure, creating unique epitopes (binding sites) that differ from the wild-type (normal) protein.
Precision: These antibodies are highly specific, meaning they can distinguish between the normal and mutated forms of a protein. This specificity allows for precise targeting of cancer or other diseased cells while sparing normal, healthy cells.
Mutant Antibodies from OriGene
Figure A, Western blot analysis of overexpressed lysate from HEK293T
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane "293T")
Figure A, Western blot analysis of overexpressed lysates(15ug per lane)
Antibody Resources |